Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MELK | Q14680 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | PNMT | P11086 | 4/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1013707 | 0.93 | NPC1 (0.53) | MELKNPC1MAPTRAB9APNMT | |
| Hydrochloric Acid SCHEMBL3118453 | 0.92 | NPC1 (0.51) | MELKNPC1MAPTRAB9APNMT | |
| SCHEMBL1790024 | 0.89 | NPC1 (0.56) | MELKNPC1MAPTRAB9ASLC2A1 | |
| SCHEMBL29835158 | 0.85 | NPC1 (0.60) | NPC1MAPTRAB9A | |
| SCHEMBL3874315 | 0.85 | NPC1 (0.60) | NPC1MAPTRAB9A | |
| SCHEMBL29589725 | 0.84 | ALDH1A1 (0.59) | MELKMAPTPNMTADRA2AADRA2B | |
| SCHEMBL1026913 | 0.84 | ALDH1A1 (0.59) | MELKMAPTPNMTADRA2AADRA2B | |
| Hydrochloric Acid SCHEMBL25276384 | 0.84 | NPC1 (0.58) | NPC1MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL30090360 | 0.84 | NPC1 (0.58) | NPC1MAPTRAB9A | |
| Hydrochloric Acid SCHEMBL15671006 | 0.83 | ALDH1A1 (0.58) | MELKMAPTPNMTADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1227803-B1 | COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITS | BELLUS HEALTH INTERNATIONAL LTD (CH) | 2010-05-05 | — | — | EP | claimed |
| US-6562836-B1 | Islet amyloid polypeptide (IAPP) is known to be capable of forming fibrils which are deposited in the pancreas of patients wtih type II diabetes | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 2003-05-13 | — | — | US | claimed |
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | disclosed |
| US-20140163042-A1 | ENZYME INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2014-06-12 | — | — | US | disclosed |
| US-20130116318-A1 | Enzyme Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2013-05-09 | — | — | US | disclosed |
| EP-1227803-B1 | COMPOUNDS FOR INHIBITING IAPP-ASSOCIATED AMYLOID DEPOSITS | BELLUS HEALTH INTERNATIONAL LTD (CH) | 2010-05-05 | — | — | EP | disclosed |
| US-7465744-B2 | Triazole compounds and the therapeutic use thereof | ABBOTT GMBH & CO. KG (DE) | 2008-12-16 | — | — | US | disclosed |
| US-7393875-B2 | Reducing islet amyloid polypeptide (IAPP) associated deposit; type II diabetes | NEUROCHEM (INTERNATIONAL) LIMITED (CH) | 2008-07-01 | — | — | US | disclosed |
| EP-1594861-B1 | TRIAZOLE COMPOUNDS AND THE THERAPEUTIC USE THEREOF | ABBOTT GMBH & CO KG (DE) | 2008-06-18 | — | — | EP | disclosed |
| US-7268142-B2 | Tetrahydroisoquinolinyl derivatives of quinazoline and isoquinoline | PFIZER INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-20060241137-A1 | Dopamine-D3-receptor antagonists/agonists; high selectivity, bioavailability and high cerebral availability; central nervous system diorders; 2-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio]propyl}-7-propionyl-1,2,3,4-tetrahydroisoquinoline | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-10-26 | — | — | US | disclosed |
| EP-1594861-A1 | TRIAZOLE COMPOUNDS AND THE THERAPEUTIC USE THEREOF | Abbott GmbH & Co. KG (DE) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004069830-A1 | TRIAZOLE COMPOUNDS AND THE THERAPEUTIC USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2004-08-19 | — | — | WO | disclosed |
| EP-0922035-B1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 2001-02-07 | — | — | EP | disclosed |
| US-6143762-A | DRUGS AS DOPAMINE ANTAGONIST PSYCHOLOGICAL DISORDERS | SMITHKLINE BEECHAM, PLC (GB) | 2000-11-07 | — | — | US | disclosed |
| EP-0922035-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 1999-06-16 | — | — | EP | disclosed |
| WO-1998006699-A1 | TETRAHYDROISOQUINOLINE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM PLC (GB) | 1998-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116318-A1 | Enzyme Inhibitors | HDAC1, HDAC11, HDAC7 | MELK 2048/4885NPC1 1650/4885MAPT 3276/4885 |
| US-20140163042-A1 | ENZYME INHIBITORS | HAT1, NR2E1, HDAC3 | MELK 3014/4885NPC1 2987/4885MAPT 4835/4885 |
| US-20060241137-A1 | Dopamine-D3-receptor antagonists/agonists; high selectivity, bioavailability and high cerebral availability; central nervous system diorders; 2-{3-[(4-methyl-5-phenyl-4H-1,2,4-triazol-3-yl)thio]propyl}-7-propionyl-1,2,3,4-tetrahydroisoquinoline | DRD3, SLC6A3, ADORA3 | MELK 3893/4885NPC1 1494/4885MAPT 1657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.